Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207790 | 0.81 | GRIN2D (0.57) | ALDH1A1MEN1LMNAKMT2AKDM4E | |
| SCHEMBL3884461 | 0.78 | TEAD3 (0.54) | ALDH1A1MEN1LMNAKMT2AKDM4E | |
| SCHEMBL3885526 | 0.78 | LTA4H (0.56) | ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL11717047 | 0.77 | ALDH1A1 (0.74) | ALDH1A1MEN1LMNAKMT2AKDM4E | |
| SCHEMBL491672 | 0.77 | HRH3 (0.79) | ALDH1A1KDM4ESMN1; SMN2HRH3 | |
| SCHEMBL6207626 | 0.76 | GRIN2D (0.65) | — | |
| SCHEMBL17848492 | 0.76 | DRD2 (0.72) | ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL492176 | 0.76 | HRH3 (0.79) | ALDH1A1KDM4ESMN1; SMN2HRH3 | |
| SCHEMBL491550 | 0.76 | HRH3 (0.79) | ALDH1A1KDM4ESMN1; SMN2HRH3 | |
| SCHEMBL15920898 | 0.76 | HRH3 (0.82) | ALDH1A1KDM4ESMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-2013197-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007102771-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | ALDH1A1 2322/4885MEN1 1450/4885LMNA 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.